Kenichi Yamaguchi

St. Luke's International Hospital, 
Tokyo, JP 
Clinical Trials:Currently Recruiting for 1 Trial
St. Luke's International Hospital, 
Tokyo, JP 

Overview

Kenichi Yamaguchi practices practicing medicine in Tokyo, Japan.

His clinical expertise encompasses Systemic Lupus Erythematosus (SLE), Juvenile Idiopathic Arthritis (JIA), and Arthritis.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

St. Luke's International Hospital, Tokyo, 1048560, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

11 Total Publications

A case report of two systemic lupus erythematosus pregnancies with early placental exposure to belimumab: Case report with review.
A case report of two systemic lupus erythematosus pregnancies with early placental exposure to belimumab: Case report with review.
Journal: Modern rheumatology case reports
Published: January 17, 2022

Frequently Asked Questions about Kenichi Yamaguchi

Is Kenichi Yamaguchi a top-rated expert for Systemic Lupus Erythematosus (SLE)?

MediFind is an objective health platform that identifies experts based on real-world data. Kenichi Yamaguchi is classified as an Experienced expert for Systemic Lupus Erythematosus (SLE), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kenichi Yamaguchi participate in research or clinical trials?

Yes. Kenichi Yamaguchi has published 11 articles and abstracts on conditions like Systemic Lupus Erythematosus (SLE). You can view a list of Kenichi Yamaguchi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yamaguchi's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile